Maternal and neonatal outcomes according to treatment strategy
| Outcomes . | No treatment (n = 137) . | IVIg (n = 47) . | Corticosteroids (n = 51) . | P value . | |
|---|---|---|---|---|---|
| All groups . | IVIg vs corticosteroids . | ||||
| Maternal response to initial treatment (n), (%) | N/A | 18 (38) | 20 (39) | — | .85 |
| Maternal platelet count at delivery (×109/L), mean (SD) | 103.2 (1.8) | 68.7 (1.8) | 77.3 (1.6) | <.0001 | .71 |
| Antepartum hemorrhage (n), (%) | 2 (1.5) | 5 (10.6) | 3 (5/9) | .08 | .39 |
| Postpartum hemorrhage (n), (%) | 6 (4.4) | 9 (19.2) | 6 (11.8) | <.03 | .33 |
| Pre-delivery platelet transfusion (n), (%) | 1 (0.7) | 6 (12.8) | 3 (5.9) | <.02 | .25 |
| Peripartum transfusion: any blood product (n), (%) | 2 (1.5) | 9 (19.2) | 3 (5.9) | .01 | .05 |
| Haemoglobin drop >30 g/L after delivery (n/N), (%) | 9/106 (8.5) | 12/47 (25.5) | 9/47 (19.2) | .02 | .39 |
| Stillbirth (n), (%) | 2 (1.5) | 0 | 2 (3.9) | .37 | .49 |
| Preterm birth <37 wk (n), (%) | 16 (11.7) | 4 (8.5) | 5 (9.8) | .81 | .99 |
| Preterm birth <34 wk (n), (%) | 7 (5.1) | 2 (4.3) | 1 (2.0) | .63 | .61 |
| Birth weight (g), mean (SD) | 3309 (637) | 3193 (769) | 3308 (521) | .54 | .38 |
| Small for gestational age (n/N), (%) | 6/136 (4.4) | 6/47 (12.8) | 5/51 (9.8) | .12 | .64 |
| Apgar score <7 at 5 min (n), (%) | 5 (3.7) | 2 (4.3) | 3 (5.9) | .80 | .99 |
| Maternal composite outcome (n), (%) | 14 (10.2) | 22 (46.8) | 12 (23.5) | <.0001 | .02 |
| Fetal/neonatal composite outcome (n), (%) | 13 (9.5) | 9 (19.2) | 9 (17.7) | .17 | .87 |
| Outcomes . | No treatment (n = 137) . | IVIg (n = 47) . | Corticosteroids (n = 51) . | P value . | |
|---|---|---|---|---|---|
| All groups . | IVIg vs corticosteroids . | ||||
| Maternal response to initial treatment (n), (%) | N/A | 18 (38) | 20 (39) | — | .85 |
| Maternal platelet count at delivery (×109/L), mean (SD) | 103.2 (1.8) | 68.7 (1.8) | 77.3 (1.6) | <.0001 | .71 |
| Antepartum hemorrhage (n), (%) | 2 (1.5) | 5 (10.6) | 3 (5/9) | .08 | .39 |
| Postpartum hemorrhage (n), (%) | 6 (4.4) | 9 (19.2) | 6 (11.8) | <.03 | .33 |
| Pre-delivery platelet transfusion (n), (%) | 1 (0.7) | 6 (12.8) | 3 (5.9) | <.02 | .25 |
| Peripartum transfusion: any blood product (n), (%) | 2 (1.5) | 9 (19.2) | 3 (5.9) | .01 | .05 |
| Haemoglobin drop >30 g/L after delivery (n/N), (%) | 9/106 (8.5) | 12/47 (25.5) | 9/47 (19.2) | .02 | .39 |
| Stillbirth (n), (%) | 2 (1.5) | 0 | 2 (3.9) | .37 | .49 |
| Preterm birth <37 wk (n), (%) | 16 (11.7) | 4 (8.5) | 5 (9.8) | .81 | .99 |
| Preterm birth <34 wk (n), (%) | 7 (5.1) | 2 (4.3) | 1 (2.0) | .63 | .61 |
| Birth weight (g), mean (SD) | 3309 (637) | 3193 (769) | 3308 (521) | .54 | .38 |
| Small for gestational age (n/N), (%) | 6/136 (4.4) | 6/47 (12.8) | 5/51 (9.8) | .12 | .64 |
| Apgar score <7 at 5 min (n), (%) | 5 (3.7) | 2 (4.3) | 3 (5.9) | .80 | .99 |
| Maternal composite outcome (n), (%) | 14 (10.2) | 22 (46.8) | 12 (23.5) | <.0001 | .02 |
| Fetal/neonatal composite outcome (n), (%) | 13 (9.5) | 9 (19.2) | 9 (17.7) | .17 | .87 |
Maternal composite outcome was defined as any adverse maternal outcome of postpartum hemorrhage, predelivery platelet transfusion, peripartum transfusion of any blood product, hemoglobin reduction of 30 g/L. Fetal/neonatal composite outcome was defined as any adverse neonatal event, including stillbirth, preterm birth before 34 wk of gestation, small for gestational age size (birth weight below 10th percentile for gestational age), or Apgar score <7 at 5 min.